- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03244137
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease is a leading cause of mortality worldwide.
It is a systemic disease which includes pulmonary, cardiac, muscular, digestive and cognitive impairments.
Pulmonary rehabilitation is a symptomatic treatment to reduce dyspnea and functional incapacity. However, it effects on cognitive dysfunction are not well known.
The aim of this study is to assess the effects of a comprehensive pulmonary rehabilitation program on cognitive dysfunction in patients with severe to very severe chronic obstructive pulmonary disease using the Montreal Cognitive Assessment tool.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Bois-Guillaume, France, 76230
- Bonnevie
-
Le Havre, France, 76600
- Médrinal
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age > 18years;
- Chronic obstructive pulmonary disease stade III to IV;
- Referred for pulmonary rehabilitation.
Non Inclusion Criteria:
- Pregnancy or likely to be;
- History of psychiatric, neuro-vascular, cognitive disease or cranial trauma;
- Active alcoholism;
- Guardianship;
- Hospitalisation for acute exacerbation of chronic obstructive pulmonary disease in the previous 4 weeks;
Exclusion Criteria:
- Interruption of the pulmonary rehabilitation program > 15 days;
- Disruption of the training before the 18th session;
- Less than 18 sessions in four month.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Pulmonary rehabilitation
The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
|
See group description.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Baseline cognitive function
Délai: Cognitive function is assessed at the beginning of the rehabilitation program : day 0
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool
|
Cognitive function is assessed at the beginning of the rehabilitation program : day 0
|
Cognitive function after pulmonary rehabilitation
Délai: Cognitive function is assessed at the end of the rehabilitation program : day 60
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool
|
Cognitive function is assessed at the end of the rehabilitation program : day 60
|
Cognitive function : follow up
Délai: Cognitive function is assessed 3 month after rehabilitation : day 150
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool
|
Cognitive function is assessed 3 month after rehabilitation : day 150
|
Change in cognitive function from baseline to the end of pulmonary rehabilitation
Délai: Change in cognitive function from baseline to the end of pulmonary rehabilitation is assessed with end of pulmonary rehabilitation minus baseline values (day 60 - day 0)
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool
|
Change in cognitive function from baseline to the end of pulmonary rehabilitation is assessed with end of pulmonary rehabilitation minus baseline values (day 60 - day 0)
|
Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up
Délai: Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up is assessed with the 3 month of follow minus the end of pulmonary rehabilitation values (day 150 - day 60)
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool
|
Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up is assessed with the 3 month of follow minus the end of pulmonary rehabilitation values (day 150 - day 60)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Anxiety and depression : baseline
Délai: Anxiety and depression are assessed at the beginning of the rehabilitation program : day 0
|
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
|
Anxiety and depression are assessed at the beginning of the rehabilitation program : day 0
|
Anxiety and depression : end of pulmonary rehabilitation
Délai: Anxiety and depression are assessed at the end of the rehabilitation program : day 60
|
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
|
Anxiety and depression are assessed at the end of the rehabilitation program : day 60
|
Anxiety and depression : follow up
Délai: Anxiety and depression are assesses 3 month after the end of pulmonary rehabilitation program : day 150
|
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
|
Anxiety and depression are assesses 3 month after the end of pulmonary rehabilitation program : day 150
|
Quality of life : baseline
Délai: Quality of life is assessed at the beginning of the rehabilitation program : day 0
|
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
|
Quality of life is assessed at the beginning of the rehabilitation program : day 0
|
Quality of life : end of pulmonary rehabilitation
Délai: Quality of life is assessed at the end of the rehabilitation program : day 60
|
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
|
Quality of life is assessed at the end of the rehabilitation program : day 60
|
Quality of life : follow-up
Délai: Quality of life is assessed 3 month after the end of the rehabilitation program : day 150
|
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
|
Quality of life is assessed 3 month after the end of the rehabilitation program : day 150
|
Functional capacity (six-minute stepper test) : baseline
Délai: Functional capacity is assessed at the beginning of the rehabilitation program : day 0
|
Functional capacity is assessed with the six-minute stepper test
|
Functional capacity is assessed at the beginning of the rehabilitation program : day 0
|
Functional capacity (six-minute stepper test) : end of pulmonary rehabilitation
Délai: Functional capacity is assessed at the end of the rehabilitation program : day 60
|
Functional capacity is assessed with the six-minute stepper test
|
Functional capacity is assessed at the end of the rehabilitation program : day 60
|
Functional capacity (six-minute walk test) : baseline
Délai: Functional capacity is assessed at the beginning of the rehabilitation program : day 0
|
Functional capacity is assessed with the six-minute walk test
|
Functional capacity is assessed at the beginning of the rehabilitation program : day 0
|
Adherence
Délai: Adherence is assessed at the end of the rehabilitation program : day 60
|
Adherence to the pulmonary rehabilitation program is assessed by the following equation : number of session performed divided by the number of scheduled sessions
|
Adherence is assessed at the end of the rehabilitation program : day 60
|
Relation between the cognitive function and the respiratory function (forced expiratory volume in 1 second)
Délai: The relation is assessed between baseline demographic data at day 0
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool and respiratory function is assessed with spirometric evaluation
|
The relation is assessed between baseline demographic data at day 0
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Cuvelier Antoine, Prof, PhD, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France.
- Chaise d'étude: Muir Jean-François, Prof, PhD, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; ADIR Association, Bois-Guillaume, France.
- Chaise d'étude: Tardif Catherine, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de physiologie urinaire, digestive, respiratoire et sportive, Bois-Guillaume, France
- Chaise d'étude: Viacroze Catherine, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de pneumologie, Bois-Guillaume, France
- Chaise d'étude: Debeaumont David, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de physiologie urinaire, digestive, respiratoire et sportive, Bois-Guillaume, France.
- Chaise d'étude: Patout Maxime, MD, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de pneumologie, Bois-Guillaume, France
- Chaise d'étude: Lamia Bouchra, Prof, PhD, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France.
- Chaise d'étude: Quieffin Jean, MD, Service de pneumologie, Hôpital Jacques Monod 76290 Montivilliers.
- Chaise d'étude: Prieur Guillaume, PT, MsC, Service de pneumologie, Groupe Hospitalier du Havre, Fr
- Chaise d'étude: Médrinal Clément, PT, MsC, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France. Service de réanimation, Groupe Hospitalier du Havre, France
- Chaise d'étude: Gravier Francis-Edouard, PT, ADIR Association, Bois-Guillaume, France
- Chaise d'étude: Bonnevie Tristan, PT, MsC, ADIR Association, Bois-Guillaume, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PR-COPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Pulmonary rehabilitation
-
Uskudar State HospitalPas encore de recrutementMaladie pulmonaire | Rééducation pulmonaire | Télésanté